Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | XIAP | P98170 | 1/20 | 1.00 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.69 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL15671104 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL16398196 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1449124 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL16398197 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL385804 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8119 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL43671 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL8118 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1331985 | 1.00 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085029-A | Enzyme-responsive controlled-release antibiotic prodrug, and preparation method and application thereof | 国家纳米科学中心 | 2024-05-28 | — | — | CN | claimed |
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2016-06-09 | — | — | US | claimed |
| WO-2015013322-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-01-29 | — | — | WO | claimed |
| US-20110275648-A1 | FLURBIPROFEN ANALOGS AND METHODS OF USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2011-11-10 | — | — | US | claimed |
| WO-2011106721-A1 | FLURBIPROFEN ANALOGS AND METHODS OF USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2011-09-01 | — | — | WO | claimed |
| EP-1053249-A2 | PEPTIDE INHIBITORS OF THE SERINE PROTEASE ACTIVITY ASSOCIATED TO THE NS3 PROTEIN OF HCV, RELEVANT USES AND PROCESS OF PRODUCTION | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2000-11-22 | — | — | EP | claimed |
| WO-1999038888-A2 | PEPTIDE INHIBITORS OF THE SERINE PROTEASE ACTIVITY ASSOCIATED TO THE NS3 PROTEIN OF HCV, RELEVANT USES AND PROCESS OF PRODUCTION | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE (IT) | 1999-08-05 | — | — | WO | claimed |
| WO-1993015042-A1 | PROCESS FOR THE PREPARATION OF D(-) AND L(+)-3,3-DIPHENYLALANINE AND D(-) AND L(+)-SUBSTITUTED 3,3-DIPHENYLALANINES AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-08-05 | — | — | WO | claimed |
| US-5198548-A | Chemical intermediates for angiotensins | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | claimed |
| CN-118085029-A | Enzyme-responsive controlled-release antibiotic prodrug, and preparation method and application thereof | 国家纳米科学中心 | 2024-05-28 | — | — | CN | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115244067-A | Synthetic antimicrobial peptides | AJK生物制药有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK BIOPHARMACEUTICAL LLC (US) | 2022-09-15 | — | — | US | disclosed |
| WO-1993021176-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993015042-A1 | PROCESS FOR THE PREPARATION OF D(-) AND L(+)-3,3-DIPHENYLALANINE AND D(-) AND L(+)-SUBSTITUTED 3,3-DIPHENYLALANINES AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993015042-A1 | PROCESS FOR THE PREPARATION OF D(-) AND L(+)-3,3-DIPHENYLALANINE AND D(-) AND L(+)-SUBSTITUTED 3,3-DIPHENYLALANINES AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
| US-5198548-A | Chemical intermediates for angiotensins | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| US-5198548-A | Chemical intermediates for angiotensins | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| US-5198548-A | Chemical intermediates for angiotensins | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159832-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | BCL3, MYLK2, BCL2L13 | SLC7A5 4177/4885PTGS1 2512/4885ALPI 882/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | SLC7A5 480/4885PTGS1 469/4885ALPI 634/4885 |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | VIP, HM13, NGLY1 | SLC7A5 1411/4885PTGS1 4504/4885ALPI 3137/4885 |
| US-20110275648-A1 | FLURBIPROFEN ANALOGS AND METHODS OF USE IN TREATING CANCER | HCAR1, AADAC, AADAT | SLC7A5 553/4885PTGS1 57/4885ALPI 557/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | SLC7A5 480/4885PTGS1 469/4885ALPI 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.